China Insurance Surplus Hits 525B Yuan Amid Scandal
China’s healthcare system presented a stark contrast on Thursday as the government announced a record surplus in the national medical insurance fund while a prominent oncologist and newly elected member of the Chinese Academy of Engineering faced explosive allegations of academic fraud linked to a “paper mill” operation.
According to the National Healthcare Security Administration, China’s basic medical insurance pooled fund recorded a current surplus of approximately 525.8 billion yuan (5257.72 billion yuan) in 2025, underscoring the financial resilience of the world’s largest healthcare safety net. The data was published in the “2025 National Medical Security Development Statistical Bulletin” on July 16.
Medical Insurance Fund: A Picture of Fiscal Health
The NHSA bulletin, reported by People’s Daily, revealed that total revenue for basic medical insurance (including maternity insurance) reached 3.59 trillion yuan in 2025, against total expenditures of 3.01 trillion yuan — a surplus margin of approximately 14.6%. The system now covers over 1.33 billion people, maintaining a coverage rate of 95%.
Key highlights include steady growth in urban employee insurance enrollment, which reached 389 million — an increase of 9.08 million year-on-year. Cross-regional medical services also surged, with 473 million patient visits for outpatient, chronic disease, and inpatient care totaling 816.2 billion yuan in expenses.
The government’s anti-fraud enforcement efforts yielded significant results: the national medical insurance system recovered 34.2 billion yuan in misused funds in 2025 alone, contributing to a cumulative recovery of 118.2 billion yuan during the 14th Five-Year Plan period.
Top Oncologist Accused of Systematic Fraud
In a starkly different narrative, Caixin Global reported that Xu Ruihua, director of Sun Yat-sen University Cancer Center and a 2025 inductee into the Chinese Academy of Engineering, has been accused of severe academic misconduct by independent science blogger Geng Tongxue.
Geng, a former PhD student at Beihang University who now commands over 1.8 million followers on Chinese social media platforms Douyin and Bilibili, posted a video on July 14 detailing systematic image duplication across multiple research papers published by Xu’s teams over nearly a decade.
The allegations center on a June 2013 paper published in the Journal of Hematology & Oncology. PubPeer analysis revealed that Western blot bands in Figure 6A were mirrored with identical outlines, band positions, and background noise — a level of duplication experts say cannot be attributed to accidental error. The cell lines used in the study, BGC-823 and SGC-7901, have been confirmed by Cellosaurus to contain HeLa contamination.
More troubling still, images from the 2013 paper reappeared in studies spanning nine years, including papers published by independent research groups at Xi’an Jiaotong University and Huazhong University of Science and Technology — institutions with no overlapping authors with Xu’s team. Geng argued this pattern strongly suggests the involvement of a third-party “paper mill” that sold fabricated data to multiple buyers.
Broader Crackdown on Academic Fraud
The Xu Ruihua case emerges amid a concerted government campaign against research misconduct. In February 2026, the National Health Commission launched a three-year initiative to eliminate paper mills and fake research, with penalties including lifetime bans from state-funded research for individuals who purchase papers or fabricate data.
As Asia Times noted, Geng Tongxue has previously targeted other high-profile figures, including respiratory disease expert Zhong Nanshan and academician Song Erwei, with several targeted scholars facing removal from administrative posts.
Implications and Outlook
The juxtaposition of these two stories highlights a fundamental tension within China’s healthcare landscape. On one hand, the NHSA’s data demonstrates a financially robust system with expanding coverage and active enforcement against insurance fraud. On the other, the Xu Ruihua scandal raises uncomfortable questions about the integrity of medical research at the highest levels of China’s scientific establishment.
Caixin reported that calls to the public relations departments of both the Chinese Academy of Engineering and Sun Yat-sen University went unanswered, leaving open the question of whether an official investigation has been launched. The outcome of this case will be closely watched as a test of whether China’s crackdown on academic fraud can reach the most senior ranks of its scientific community.
For now, China’s healthcare system presents two faces: one of institutional strength and financial stability, and another of systemic integrity challenges that even the nation’s most honored medical scientists may not be immune to.